ViroMed to conduct phase II trial of VM202
Published: 2008-11-11 06:24:00
Updated: 2008-11-11 06:24:00
ViroMed president Kim Sung-young said that she had a meeting with some of the US investigators and clinicians in New Orleans on November 8 in order to further evaluate the clinical benefit of VM202 through its planned Phase II trial.
In the US in phase I, a dose-escalation study, was carried o...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
